This webinar discusses RNA sequencing as an alternative to immunohistochemistry (IHC) in selecting patients for cancer immunotherapy.

Recent progress in our understanding of the complex conditions required to activate a therapeutically relevant tumor-targeting immune response revealed several challenges in personalizing cancer immunotherapy. Currently, patient selection for standalone PD-1 checkpoint inhibition relies on the assessment of PD-L1 expression levels by IHC, which does not provide satisfactory stratification.

In this webinar, speakers from Roswell Park Cancer Institute, Weill Cornell Medical College, and OmniSeq provide an overview on the fundamentals of cancer immunotherapy and demonstrate that RNAseq offers a superior alternative to IHC for simultaneously measuring multiple immunological markers towards improved patient selection.

The presentations include several cases of patients treated with checkpoint inhibitors at Roswell Park Cancer Institute.